In this study, we investigated the potential for XPO1 inhibitors to modulate NK cell activation against CLL cells in combination with BTK inhibitors and anti-CD20 antibodies, as well in the presence of microenvironmental signals that mimic lymph node support. The gene discussed is XPO1; the disease is B-cell chronic lymphocytic leukemia.